DexCom Inc (DXCM)

NASDAQ
Currency in USD
89.07
+4.98(+5.92%)
Closed
After Hours
89.25+0.18(+0.20%)
DXCM Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
Fair Value
Day's Range
86.0089.84
52 wk Range
62.34142.00
Key Statistics
Edit
Prev. Close
84.09
Open
86.03
Day's Range
86-89.84
52 wk Range
62.34-142
Volume
7.59M
Average Volume (3m)
3.51M
1-Year Change
-23.9%
Book Value / Share
5.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
100.19
Upside
+12.48%
Members' Sentiments
Bearish
Bullish
ProTips
13 analysts have revised their earnings downwards for the upcoming period
Show more

DexCom Inc Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc SWOT Analysis


CGM Market Leade
DexCom, a pioneer in continuous glucose monitoring, faces challenges amid stock volatility while pursuing growth in the evolving diabetes care landscape
Stelo CGM Launch
Explore DexCom's strategic move into the non-insulin using diabetes market, targeting 125 million potential users with competitive pricing models
Financial Outlook
Analysts project mid-teens revenue growth despite recent setbacks, with EPS estimates ranging from $1.70 to $2.15 for fiscal years 2024 and 2025
Competitive Dynamics
Delve into DexCom's battle for market share against Abbott Laboratories, particularly in DME and AID systems, and its focus on innovation to maintain leadership
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q3/2024

  • DexCom reported 3% organic revenue growth to $994M in Q3 2024, with 12% international growth offsetting 2% U.S. decline
  • 2024 revenue guidance maintained at $4.00-$4.05B; company targets $4.6B revenue by 2025 with focus on long-term growth
  • Stelo launch for pre-diabetes and Type 2 diabetes shows strong early adoption; 15-day G7 CGM system awaits FDA approval
  • International market access improvements, especially in Japan and France, expected to drive significant future growth
  • U.S. installed base grew 27-28% YoY, despite slower new customer starts and increased rebate eligibility impacting revenue
Last Updated: 25/10/2024, 21:54
Read Full Transcript

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
60.4x−3.8x−0.7x
PEG Ratio
6.46−0.020.00
Price/Book
16.6x1.9x2.6x
Price / LTM Sales
8.6x1.6x3.1x
Upside (Analyst Target)
12.3%46.2%47.6%
Fair Value Upside
Unlock18.6%7.7%Unlock

Analyst Ratings

20 Buy
4 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 100.19
(+12.48% Upside)

Earnings

Latest Release
Feb 13, 2025
EPS / Forecast
0.45 / 0.52
Revenue / Forecast
1.11B / 1.10B
EPS Revisions
Last 90 days

People Also Watch

317.30
CEG
+1.87%
684.93
MPWR
-2.15%
366.68
LULU
-6.18%
167.66
VST
+1.21%
228.68
AMZN
-0.73%

FAQ

What Is the DexCom (DXCM) Premarket Price Today?

The DexCom (DXCM) premarket price is . Premarket price change units: . Premarket percentage change: . Premarket volume: . Current date: 18 Feb 2025. Previous close: 84.09

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 34.80B.

What is DexCom Earnings Per Share?

The DexCom EPS is 1.46.

What Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on 23 Apr 2025.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.